Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › capecitabine

capecitabine

13 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of capecitabine

203 trials tracked of capecitabine: 51 in phase 3 or 4 and 26 with published results. The most-cited published study has 685 citations.

203Trials tracked
51Phase 3 & 4
0Recruiting
26With published results
Phase distribution
Phase 4 2 Phase 3 49 Phase 2 127 Phase 1 18 Other / NA 7
  1. Phase 3 Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) Completed · 685 cited
  2. Phase 3 Maintenance Treatment With Capecitabine Versus Observation in Breast Cancer Patients Completed · 684 cited
  3. Phase 3 A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting Completed · 608 cited
  4. Phase 3 Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) Completed · 607 cited
  5. Phase 3 Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) Completed · 489 cited
  6. Phase 3 A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer Completed · 476 cited
Show 44 more trials
  1. Phase 3 Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062) Completed · 441 cited
  2. Phase 3 Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer Completed · 413 cited
  3. Phase 3 DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] Completed · 338 cited
  4. Phase 3 Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) Completed · 334 cited
  5. Phase 3 A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma Completed · 286 cited
  6. Phase 3 A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer Completed · 282 cited
  7. Phase 3 Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) Completed · 222 cited
  8. Phase 3 Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer Completed · 212 cited
  9. Phase 3 Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC) Completed · 149 cited
  10. Phase 3 Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors Completed · 132 cited
  11. Phase 3 Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122) Completed · 105 cited
  12. Phase 3 EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer Completed · 74 cited
  13. Phase 3 Optimization of Bevacizumab Scheduling With Chemotherapy for Metastatic Colorectal Cancer Completed · 34 cited
  14. Phase 3 Standard Versus Continuous Capecitabine in Advanced Breast Cancer Completed · 24 cited
  15. Phase 4 A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer Completed · 18 cited
  16. Phase 3 Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015) Completed · 14 cited
  17. Phase 3 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Completed · 13 cited
  18. Phase 3 Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003) Completed · 13 cited
  19. Phase 3 Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer Completed · 12 cited
  20. Phase 3 Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma Completed · 7 cited
  21. Phase 4 A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer Completed
  22. Phase 3 A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA) Completed
  23. Phase 3 A Study of Bevacizumab (Avastin) Versus Placebo in Combination With Capecitabine (Xeloda) and Cisplatin as First-Line Therapy for Advanced Gastric Cancer Completed
  24. Phase 3 Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Completed
  25. Phase 3 Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer Completed
  26. Phase 3 Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension Completed
  27. Phase 3 A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer Completed
  28. Phase 3 E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes Completed
  29. Phase 3 LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib Completed
  30. Phase 3 A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer Completed
  31. Phase 3 Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer Completed
  32. Phase 3 A Study of Bevacizumab (Avastin) in Combination With Capecitabine (Xeloda) in Elderly Patients With Metastatic Colorectal Cancer Completed
  33. Phase 3 Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Completed
  34. Phase 3 ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer Completed
  35. Phase 3 Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer Completed
  36. Phase 3 A Phase III Trial For Patients With Metastatic Breast Cancer Completed
  37. Phase 3 The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (P04445/MK-2746-071) Completed
  38. Phase 3 A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer Completed
  39. Phase 3 Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Completed
  40. Phase 3 Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer Completed
  41. Phase 3 Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer Completed
  42. Phase 3 Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer Completed
  43. Phase 3 A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer Completed
  44. Phase 3 A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer Completed

Showing the 50 most-cited and recently-updated of 203 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Datopotamab deruxtecan showed no overall survival benefit versus investigator's choice chemotherapy in metastatic HR-positive breast cancer.
OB/GYN & Women's Health RCT
Datopotamab deruxtecan showed no overall survival benefit versus investigator's choice chemotherapy in metastatic HR-positive breast cancer. Datopotamab deruxtecan extends life for advanced breast cancer patients
This Phase III randomized controlled trial evaluated datopotamab deruxtecan versus investigator's choice chemotherapy in patients with inope…
New drug datopotamab deruxtecan helps advanced breast cancer patients live longer and stay disease-free
Jun 4, 2026
Oxaliplatin addition to rectal cancer chemoradiation improves tumor regression
Gastroenterology RCT
Oxaliplatin addition to rectal cancer chemoradiation improves tumor regression Adding oxaliplatin to radiation helps tumor shrink but does not improve long-term survival for high-risk rectal cancer patients
Adding oxaliplatin to capecitabine chemoradiation for high-risk rectal cancer significantly improved tumor regression rates, but did not enh…
Adding oxaliplatin to standard radiation therapy helped tumors shrink more in high-risk rectal cancer patients, yet it did not improve long-…
Jun 2, 2026
Fulvestrant maintenance improves PFS versus capecitabine in HR+ HER2- metastatic breast cancer
Oncology RCT
Fulvestrant maintenance improves PFS versus capecitabine in HR+ HER2- metastatic breast cancer Fulvestrant maintenance therapy significantly improves progression free survival compared to capecitabine in hormone receptor positive metastatic breast cancer patients
This randomized phase 3 trial in 210 patients with HR+ HER2- metastatic breast cancer compared fulvestrant to capecitabine after first-line …
In a study of 210 patients in China, fulvestrant helped keep cancer from growing longer than capecitabine. Fewer serious side effects occurr…
May 22, 2026
Review covers capecitabine and trastuzumab emtansine for triple-negative and HER2-positive breast cancer
Oncology Sys. Review
Review covers capecitabine and trastuzumab emtansine for triple-negative and HER2-positive breast cancer Breast Cancer Chemo Is Getting Smarter and More Effective
This narrative review examines emerging therapies for women with breast cancer, including triple-negative and HER2-positive disease. The aut…
New blood tests and tumor markers are helping doctors choose the right chemo for breast cancer, reducing resistance and improving survival.
Frontiers May 8, 2026
Meta-analysis of pucotenlimab shows improved outcomes across multiple solid tumors
Oncology Meta-analysis
Meta-analysis of pucotenlimab shows improved outcomes across multiple solid tumors New analysis shows pucotenlimab improves outcomes for several solid tumor types
This meta-analysis evaluated pucotenlimab (HX008) in patients with gastric, gastroesophageal junction, triple-negative breast cancer, melano…
A new analysis of pucotenlimab shows significantly improved outcomes versus control for patients with gastric cancer, triple-negative breast…
May 1, 2026
Network meta-analysis of pharmacological interventions for hand-foot syndrome in cancer patients undergoing chemotherapy
Oncology Meta-analysis
Network meta-analysis of pharmacological interventions for hand-foot syndrome in cancer patients undergoing chemotherapy Simple cream could stop painful hand and foot syndrome side effects
This network meta-analysis evaluated pharmacological interventions for hand-foot syndrome prevention in cancer patients undergoing chemother…
New research suggests a common pain cream could protect cancer patients from painful hand and foot syndrome during treatment.
Apr 29, 2026
Tumor debulking plus chemotherapy did not improve overall survival in multiorgan metastatic colorectal cancer patients
Oncology RCT
Tumor debulking plus chemotherapy did not improve overall survival in multiorgan metastatic colorectal cancer patients Surgery Doesn’t Extend Life for Advanced Colon Cancer
This randomized clinical trial enrolled 382 adult patients with multiorgan metastatic colorectal cancer across 27 hospitals in the Netherlan…
This large study shows that removing tumors in advanced colon cancer doesn’t help people live longer.
JAMA Apr 23, 2026
Tucidinostat plus capecitabine shows 25.8% response in advanced HR-positive HER2-negative breast cancer
Oncology Phase II
Tucidinostat plus capecitabine shows 25.8% response in advanced HR-positive HER2-negative breast cancer New Drug Combo Helps Breast Cancer After CDK4/6 Failure
This phase 2 trial evaluated tucidinostat plus metronomic capecitabine with endocrine therapy in 66 patients with HR-positive HER2-negative …
A new drug mix shrinks tumors in advanced breast cancer patients whose disease grew after standard treatments failed.
Apr 17, 2026
Phase II RCT finds no benefit for adding capecitabine to 177Lu-Dotatate in advanced NETs
Oncology RCT
Phase II RCT finds no benefit for adding capecitabine to 177Lu-Dotatate in advanced NETs Adding a Drug Actually Hurted These Patients
A Phase II randomized controlled trial in 111 patients with advanced somatostatin receptor-positive GEP or bronchopulmonary NETs compared…
Adding a common chemotherapy drug to cancer treatment actually made tumors grow faster and reduced survival time for these patients.
Apr 16, 2026
Subcutaneous PEG-rhG-CSF reduced grade ≥3 neutropenia and CIN in GI cancer patients receiving oral chemotherapy
Oncology RCT
Subcutaneous PEG-rhG-CSF reduced grade ≥3 neutropenia and CIN in GI cancer patients receiving oral chemotherapy New Shot Cuts Severe Low White Blood Cell Risk
This prospective, single-center, open-label, exploratory, non-randomized controlled study evaluated subcutaneous PEG-rhG-CSF in 43 gastroint…
A simple shot given before chemotherapy could keep your body's infection-fighting cells strong when taking oral cancer pills.
Frontiers Apr 16, 2026
Neoadjuvant CAPOX chemotherapy alone showed comparable survival to chemoradiotherapy in locally advanced rectal cancer with uninvolved mesorectal fascia
Oncology RCT
Neoadjuvant CAPOX chemotherapy alone showed comparable survival to chemoradiotherapy in locally advanced rectal cancer with uninvolved mesorectal fascia Some Rectal Cancer Patients May Skip Radiation Without Losing Ground
This Phase III RCT compared 4 cycles of CAPOX chemotherapy alone versus chemoradiotherapy in patients with locally advanced rectal cancer an…
Some rectal cancer patients can skip pre-surgery radiation and still achieve similar cure rates while avoiding long-term side effects like b…
Apr 13, 2026
Envafolimab plus lenvatinib and capecitabine shows activity in resected biliary tract cancer
Oncology Phase II
Envafolimab plus lenvatinib and capecitabine shows activity in resected biliary tract cancer Combination therapy shows promise for preventing biliary tract cancer recurrence after surgery
A single-arm phase II trial in 28 patients with resected biliary tract cancer at high risk of recurrence found median disease-free survival …
A new three-drug combination helped 68% of high-risk biliary tract cancer patients stay cancer-free for a year after surgery, with 91% still…
Apr 2, 2026

All capecitabine Articles